Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Rocket One
Historiska aktiekurser
Aktuell aktiekurs	US$1.46
52 veckors högsta	US$2.20
52 veckors lägsta	US$0.49
Beta	0.58
1 månads förändring	99.70%
3 månaders förändring	43.14%
1 års förändring	75.84%
3 års förändring	-21.35%
5 års förändring	-96.23%
Förändring sedan börsintroduktionen	-99.32%

Senaste nyheter och uppdateringar

Recent updates

Analysartikel • Sep 08

Hoth Therapeutics (NASDAQ: HOTH): Small-Cap Biotech Pairing Clinical Breakthroughs with AI Innovation

Hoth Therapeutics (NASDAQ: HOTH) is emerging as one of the most intriguing small-cap biotech stories on the market. With a market capitalization of just ~$16 million, the company is combining tangible clinical success with cutting-edge AI tools, creating a potentially asymmetric investment opportunity.

Analysartikel • Sep 05

Weekly Picks: 💸 A fintech heavyweight with even more upside potential and 2 more picks

This week’s picks cover: Why Venmo and merchant solutions are driving PayPal’s upside potential, how IREN’s pivot from Bitcoin mining to AI infrastructure is adding value, and how Cadeler’s fleet expansion rides offshore wind growth.

Uppdatering av berättelse • Sep 05

100% Patient Improvement in trial puts this $16M Biotech on the radar

Strengthening Pipeline with Breakthrough AI Hoth Therapeutics (NASDAQ: HOTH) is layering cutting-edge technology on top of its strong clinical momentum. Already known for its standout Phase 2 trial results (100% patient improvement with HT-001 cancer rash trial), Hoth is now integrating Lantern Pharma’s PredictBBB.ai platform , an AI tool with 94% accuracy in predicting whether drugs can cross the blood–brain barrier (BBB).

Ny berättelse • Sep 01

100% Patient Improvement in trial puts this $16M Biotech on the radar

Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.

Seeking Alpha • Sep 20

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Hoth Therapeutics (NASDAQ:HOTH) said on Tuesday it had signed an agreement with Altasciences to develop and manufacture the HT-TBI drug product formulation for the treatment and/or prevention of secondary brain injury. HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel. "We are leveraging Altasciences' expertise to develop and manufacture novel parenteral formulations to achieve a formulation that requires no preparation or special storage requirements to ensure HT-TBI can be used anywhere in the field at the time a head injury or stroke occurs," the company said.

Seeking Alpha • Jun 29

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Nasdaq has granted Hoth Therapeutics (NASDAQ:HOTH) an additional 180-days or until December 26, 2022 to regain compliance with minimum $1.00 closing bid price per share requirement. In a letter dated December 30, 2021, the company was notified that the minimum bid price per share for its common shares has been below $1.00 for a period of 30 consecutive business days and it no longer meets the minimum bid price requirements. The company having provided written notice of its intention to cure the deficiency during the Additional Compliance Period, including by effecting a reverse stock split, if necessary. If the company does not comply with the minimum bid price requirement during the 180-day grace period than its shares are subject to delisting. Shares plunged around 72% over a period of one year.

Aktieägarnas avkastning

	RKTO	US Pharmaceuticals	US Marknad
7D	111.6%	0.1%	1.6%
1Y	75.8%	41.1%	28.5%

Avkastning vs industri: RKTO översteg US Pharmaceuticals branschen som gav 41.1 % under det senaste året.

Avkastning vs Marknaden: RKTO översteg US marknaden som gav 28.5 % under det senaste året.

Prisvolatilitet

Is RKTO's price volatile compared to industry and market?
RKTO volatility
RKTO Average Weekly Movement	31.3%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Stabil aktiekurs: RKTO s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: RKTO s veckovolatilitet har ökat från 20% till 31% under det senaste året.

Om företaget

Grundad	Anställda	VD OCH KONCERNCHEF	Webbplats
2017	3	Robb Knie	www.rocketone.space

Rocket One Inc. fokuserar på att utveckla och kommersialisera infrastruktur för AI-halvledare. Företaget utvecklar också AI-chip och minneshårdvara som är konstruerad för orbitala miljöer och miljöer med hög strålning, inklusive nästa generations nanomagnetiska AI-chipteknik. Företaget erbjuder halvledarinfrastruktur som bygger på nanomagnetisk och spintronisk datorteknik som är utformad för att hantera dessa begränsningar på hårdvarunivå.

Rocket One Inc. Sammanfattning av grunderna

Hur förhåller sig Rocket One:s resultat och omsättning till dess börsvärde?
RKTO grundläggande statistik
Börsvärde	US$27.93m
Vinst(TTM)	-US$11.69m
Intäkter(TTM)	n/a

0.0x

P/S-förhållande

-2.4x

P/E-förhållande

Är RKTO övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
RKTO resultaträkning (TTM)
Intäkter	US$0
Kostnad för intäkter	US$0
Bruttovinst	US$0
Övriga kostnader	US$11.69m
Intäkter	-US$11.69m

Senast redovisade vinst

Mar 31, 2026

Nästa vinstdatum

n/a

Vinst per aktie (EPS)	-0.61
Bruttomarginal	0.00%
Nettovinstmarginal	0.00%
Skuld/egenkapitalförhållande	0%

Hur har RKTO utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/31 12:33
Aktiekurs vid dagens slut	2026/05/29 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Rocket One Inc. bevakas av 1 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Jason Kolbert	D. Boral Capital LLC.

Rocket One (RKTO) Aktievy

Riskanalys

Top Community Narratives

100% Patient Improvement in trial puts this $16M Biotech on the radar

Top Community Narratives

100% Patient Improvement in trial puts this $16M Biotech on the radar

Rocket One Inc. Konkurrenter

IGC Pharma

MariMed

TherapeuticsMD

Aytu BioPharma

Prishistorik och prestanda

Senaste nyheter och uppdateringar

New major risk - Share price stability

Hoth Therapeutics Receives U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform

Hoth Therapeutics, Inc. Secures European Authorization In Spain For HT-001 Phase 2a Trial As Interim Data Show Strong Efficacy In Cancer Patients

Hoth Therapeutics, Inc. Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement

Hoth Therapeutics Reports Positive Data for GDNF in Liver Fat Metabolism and Outperforms Semaglutide

New major risk - Shareholder dilution

Recent updates

New major risk - Share price stability

Hoth Therapeutics Receives U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform

Hoth Therapeutics, Inc. Secures European Authorization In Spain For HT-001 Phase 2a Trial As Interim Data Show Strong Efficacy In Cancer Patients

Hoth Therapeutics, Inc. Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement

Hoth Therapeutics Reports Positive Data for GDNF in Liver Fat Metabolism and Outperforms Semaglutide

New major risk - Shareholder dilution

Hoth Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

New minor risk - Share price stability

Hoth Therapeutics Announces Positive Clinical Results for HT-001 Program

Hoth Therapeutics Inc Deploys OpenClaw AI Platform to Accelerate Drug Discovery

Hoth Therapeutics Reports Positive HT-001 Pharmacokinetic, Safety, and Clinical Activity Data in Cancer Patients with EFGR Therapy-Associated Skin Toxicities

Hoth Therapeutics Reports Positive Female Preclinical Data Showing Ht-Va Restores Cholesterol Levels and Improves Lipid Metabolism in Masld Model

Hoth Therapeutics, Inc. Announces Significant Expansion of Its Cleer-001 Phase 2A Clinical Trial with the Addition of Regis Clinical Research as A New Enrolling Site

Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's Ht-Va Gdnf Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Hoth Therapeutics, Inc. Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated Ht-Kit, Advancing Ht-001 Phase 2, and New Gdnf Metabolic Program

New major risk - Financial position

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rarec-KIT-Driven Cancers

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Hoth Therapeutics, Inc. Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and Menin Inhibitor-Associated Skin Toxicities

Hoth Therapeutics, Inc. Announces Expansion of Phase II Clinical Trial Infrastructure

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Hoth Therapeutics (NASDAQ: HOTH): Small-Cap Biotech Pairing Clinical Breakthroughs with AI Innovation

Weekly Picks: 💸 A fintech heavyweight with even more upside potential and 2 more picks

100% Patient Improvement in trial puts this $16M Biotech on the radar

Hoth Therapeutics Inc.'s Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones with Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

100% Patient Improvement in trial puts this $16M Biotech on the radar

Hoth Therapeutics HT-001 Interim Results First-In-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway

Hoth Therapeutics, Inc., Annual General Meeting, Aug 05, 2025

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics, Inc. Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Receives Notice of Delisting Due to Non-Compliance with Nasdaq Bid Price

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive Kit-Driven Cancers

Hoth Therapeutics Receives Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Hoth Therapeutics, Inc. Announces Board and Committee Changes, Effective as of April 15, 2025

Hoth Therapeutics Announces Positive Initial Data in Phase 2A Clinical Trial

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease

New major risk - Financial position

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for Ht-001 to Support Cancer Patients in Need

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Hoth Therapeutics Regains Compliance with Nasdaq Listing Rules

Hoth Therapeutics, Inc. Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.7 million.

Hoth Therapeutics Notifies by the Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirements

Hoth Therapeutics, Inc. Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Hoth Therapeutics, Inc. Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

New major risk - Share price stability

Price target decreased by 14% to US$4.50

New minor risk - Share price stability

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics, Inc. Expands Clinical Trial for Cancer Patients

New major risk - Shareholder dilution

Hoth Therapeutics, Inc., Annual General Meeting, Aug 07, 2024

New major risk - Financial position